JOP20210262A1 - تركيبة صيدلانية، تشمل متغير ودواء هيالورونيداز ph20 البشرى، للحقن تحت الجلد - Google Patents
تركيبة صيدلانية، تشمل متغير ودواء هيالورونيداز ph20 البشرى، للحقن تحت الجلدInfo
- Publication number
- JOP20210262A1 JOP20210262A1 JOP/2021/0262A JOP20210262A JOP20210262A1 JO P20210262 A1 JOP20210262 A1 JO P20210262A1 JO P20210262 A JOP20210262 A JO P20210262A JO P20210262 A1 JOP20210262 A1 JO P20210262A1
- Authority
- JO
- Jordan
- Prior art keywords
- pharmaceutical composition
- human
- variant
- present disclosure
- drug
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 3
- 101001041117 Homo sapiens Hyaluronidase PH-20 Proteins 0.000 title 1
- 238000010254 subcutaneous injection Methods 0.000 title 1
- 239000007929 subcutaneous injection Substances 0.000 title 1
- 101100178973 Homo sapiens SPAM1 gene Proteins 0.000 abstract 4
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
يتعلق الكشف الحالي بتركيبة صيدلانية تشمل (أ) دواء و(ب) متغير PH20 بشري. يشتمل متغير PH20 البشري الموجود في التركيبة الصيدلانية وفقًا للكشف الحالي على بديل (بدائل) متخلفات الحمض الأميني في منطقة أو أكثر مختارة من منطقة alpha-helix 8 (S347 إلى C381) ومنطقة رابط (A333 إلى R346) بين alpha-helix 7 وalpha-helix 8 في PH20 البشري من النوع البري الذي يحتوي على سلسلة الأحماض الأمينية لمتوالية برقم تعريف: 1، حيث يتم شق متخلف (متخلفات) الأحماض الأمينية الموجود في الطرف N أو الطرف C بشكل انتقائي. بالإضافة إلى ذلك، يمكن أيضًا أن تشتمل التركيبة الصيدلانية وفقًا للكشف الحالي على مادة مضافة مقبولة صيدلانيًا، خاصة مادة مثبتة. يمكن للتركيبة الصيدلانية وفقًا للكشف الحالي أن تزيد من التأثير العلاجي للدواء المستخدم في توليفة معه، نظرًا لتأثير متغيرات PH20 البشرية.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190033880 | 2019-03-25 | ||
PCT/KR2020/003975 WO2020197230A1 (ko) | 2019-03-25 | 2020-03-24 | 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20210262A1 true JOP20210262A1 (ar) | 2023-01-30 |
Family
ID=72611090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2021/0262A JOP20210262A1 (ar) | 2019-03-25 | 2020-03-24 | تركيبة صيدلانية، تشمل متغير ودواء هيالورونيداز ph20 البشرى، للحقن تحت الجلد |
Country Status (22)
Country | Link |
---|---|
US (2) | US20210363270A1 (ar) |
EP (1) | EP3785701A4 (ar) |
JP (3) | JP7295150B2 (ar) |
KR (3) | KR102507853B1 (ar) |
CN (3) | CN116870164A (ar) |
AU (2) | AU2020248612B9 (ar) |
BR (1) | BR112021019076A2 (ar) |
CA (1) | CA3131052A1 (ar) |
CL (1) | CL2021002464A1 (ar) |
CO (1) | CO2021012380A2 (ar) |
CR (1) | CR20210489A (ar) |
DO (1) | DOP2021000197A (ar) |
EA (1) | EA202192588A1 (ar) |
EC (1) | ECSP21070640A (ar) |
IL (1) | IL286539A (ar) |
JO (1) | JOP20210262A1 (ar) |
MX (1) | MX2021011278A (ar) |
NI (1) | NI202100085A (ar) |
PE (1) | PE20220283A1 (ar) |
SG (1) | SG11202110512WA (ar) |
WO (1) | WO2020197230A1 (ar) |
ZA (2) | ZA202108027B (ar) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013102144A2 (en) | 2011-12-30 | 2013-07-04 | Halozyme, Inc. | Ph20 polypeptede variants, formulations and uses thereof |
WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
CN116585466A (zh) | 2018-05-10 | 2023-08-15 | 瑞泽恩制药公司 | 含有高浓度vegf受体融合蛋白的制剂 |
JP7204729B2 (ja) * | 2018-07-25 | 2023-01-16 | アルテオゼン インコーポレイテッド | 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 |
KR20230031981A (ko) | 2019-05-14 | 2023-03-07 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
KR20220069045A (ko) * | 2020-01-23 | 2022-05-26 | (주)알테오젠 | 안정성이 향상된 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물 |
WO2021252917A2 (en) | 2020-06-11 | 2021-12-16 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
IL303350A (en) | 2020-12-04 | 2023-08-01 | Macrogenics Inc | Preparations containing an antibody against HER2/NEU and their use |
US20220233693A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Antibody Compositions and Methods of Use Thereof |
CA3196999A1 (en) | 2020-12-28 | 2022-07-07 | Masano HUANG | Methods of treating tumors |
IL310608A (en) | 2021-08-02 | 2024-04-01 | argenx BV | Dosage forms for subcutaneous administration |
CN118139636A (zh) | 2021-09-14 | 2024-06-04 | 武田药品工业株式会社 | 使用透明质酸酶的经促进的浓缩抗体制剂的递送 |
WO2023075506A1 (ko) * | 2021-10-29 | 2023-05-04 | (주)알테오젠 | 인간 히알루로니다제 ph20과 약물을 포함하는 약학 조성물 |
WO2023168305A1 (en) | 2022-03-01 | 2023-09-07 | Exuma Biotech Corp. | Viral particles with membrane-bound hyaluronidase |
WO2023169986A1 (en) * | 2022-03-07 | 2023-09-14 | Mabxience Research, S.L. | Stable formulations for antibodies |
KR20230150203A (ko) * | 2022-04-20 | 2023-10-30 | 주식회사 알토스바이오로직스 | 오크렐리주맙(Ocrelizumab)을 포함하는 약학적 조성물과 그의 용도 |
WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
CA3240340A1 (en) * | 2022-06-22 | 2023-12-28 | Soon Jae Park | N-terminal and/or c-terminal cleaved soluble ph20 polypeptide and use thereof |
WO2024005502A1 (ko) * | 2022-06-29 | 2024-01-04 | 주식회사 오디스젠 | 중성 ph에서 활성을 나타내는 히알루로니다제 hyal1 변이체 |
KR20240038901A (ko) * | 2022-09-16 | 2024-03-26 | (주)피앤피바이오팜 | 신규한 히알루로니다제 ph-20 변이체 및 그 용도 |
WO2024117476A1 (ko) * | 2022-11-28 | 2024-06-06 | 주식회사 대웅제약 | 생체이용률이 개선된 니클로사마이드 함유 조성물 |
KR102554775B1 (ko) * | 2023-02-07 | 2023-07-12 | 한국코러스 주식회사 | 히알루로니다제의 안정화제 및 이를 포함하는 히알루로니다제 제형 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2517145C (en) * | 2003-03-05 | 2017-08-01 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
CN101384621A (zh) | 2005-11-10 | 2009-03-11 | 受体生物公司 | 产生受体和配体同种型的方法 |
TWI489994B (zh) * | 2008-03-17 | 2015-07-01 | Baxter Healthcare Sa | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
NZ588638A (en) * | 2008-04-14 | 2012-09-28 | Halozyme Inc | Screening method for identifying a subject for treatment with a modified hyaluronidase polypeptides |
WO2010077297A1 (en) * | 2008-12-09 | 2010-07-08 | Halozyme, Inc. | Extended soluble ph20 polypeptides and uses thereof |
US9345661B2 (en) * | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
WO2013102144A2 (en) * | 2011-12-30 | 2013-07-04 | Halozyme, Inc. | Ph20 polypeptede variants, formulations and uses thereof |
TW201534726A (zh) | 2013-07-03 | 2015-09-16 | Halozyme Inc | 熱穩定ph20玻尿酸酶變異體及其用途 |
JP6537076B2 (ja) * | 2014-07-31 | 2019-07-03 | 国立大学法人神戸大学 | 分泌シグナルペプチドならびにそれを利用したタンパク質の分泌および細胞表層提示 |
WO2016033555A1 (en) * | 2014-08-28 | 2016-03-03 | Halozyme, Inc. | Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor |
WO2018102372A1 (en) * | 2016-11-30 | 2018-06-07 | Memorial Sloan Kettering Cancer Center | Inhibitor-functionalized ultrasmall nanoparticles and methods thereof |
CN114984206A (zh) * | 2017-03-02 | 2022-09-02 | 基因泰克公司 | Her2阳性乳腺癌的辅助治疗 |
JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
JP7204729B2 (ja) * | 2018-07-25 | 2023-01-16 | アルテオゼン インコーポレイテッド | 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 |
-
2020
- 2020-03-24 EP EP20776465.5A patent/EP3785701A4/en active Pending
- 2020-03-24 CA CA3131052A patent/CA3131052A1/en active Pending
- 2020-03-24 AU AU2020248612A patent/AU2020248612B9/en active Active
- 2020-03-24 CN CN202310416462.0A patent/CN116870164A/zh active Pending
- 2020-03-24 MX MX2021011278A patent/MX2021011278A/es unknown
- 2020-03-24 WO PCT/KR2020/003975 patent/WO2020197230A1/ko active Application Filing
- 2020-03-24 JO JOP/2021/0262A patent/JOP20210262A1/ar unknown
- 2020-03-24 CN CN202080003052.8A patent/CN112203642A/zh active Pending
- 2020-03-24 EA EA202192588A patent/EA202192588A1/ru unknown
- 2020-03-24 KR KR1020227016935A patent/KR102507853B1/ko active IP Right Grant
- 2020-03-24 SG SG11202110512WA patent/SG11202110512WA/en unknown
- 2020-03-24 BR BR112021019076A patent/BR112021019076A2/pt unknown
- 2020-03-24 JP JP2020569741A patent/JP7295150B2/ja active Active
- 2020-03-24 CN CN202310758097.1A patent/CN117100867A/zh active Pending
- 2020-03-24 US US17/052,952 patent/US20210363270A1/en active Pending
- 2020-03-24 KR KR1020207030248A patent/KR102650991B1/ko active IP Right Grant
- 2020-03-24 CR CR20210489A patent/CR20210489A/es unknown
- 2020-03-24 PE PE2021001563A patent/PE20220283A1/es unknown
- 2020-03-24 KR KR1020237007559A patent/KR20230037691A/ko active Search and Examination
-
2021
- 2021-09-19 IL IL286539A patent/IL286539A/en unknown
- 2021-09-22 NI NI202100085A patent/NI202100085A/es unknown
- 2021-09-22 CO CONC2021/0012380A patent/CO2021012380A2/es unknown
- 2021-09-22 EC ECSENADI202170640A patent/ECSP21070640A/es unknown
- 2021-09-22 DO DO2021000197A patent/DOP2021000197A/es unknown
- 2021-09-22 CL CL2021002464A patent/CL2021002464A1/es unknown
- 2021-10-20 ZA ZA2021/08027A patent/ZA202108027B/en unknown
-
2022
- 2022-04-18 JP JP2022068166A patent/JP7166478B2/ja active Active
- 2022-05-13 US US17/744,575 patent/US20220289864A1/en active Pending
- 2022-08-22 ZA ZA2022/09369A patent/ZA202209369B/en unknown
-
2023
- 2023-02-24 JP JP2023026863A patent/JP2023078146A/ja active Pending
-
2024
- 2024-02-23 AU AU2024201238A patent/AU2024201238A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20210262A1 (ar) | تركيبة صيدلانية، تشمل متغير ودواء هيالورونيداز ph20 البشرى، للحقن تحت الجلد | |
AU2019311658A8 (en) | Novel hyaluronidase variants and pharmaceutical composition comprising the same | |
MX2022008060A (es) | Nuevas variantes de hialuronidasa con estabilidad mejorada y composicion farmaceutica que contiene la misma. | |
US9221886B2 (en) | Supercharged proteins for cell penetration | |
EP2750686B1 (en) | Polypeptide comprising frataxin and a c-terminal mitochondria penetrating peptide for use in the treatment of friedreich's ataxia | |
EA039105B1 (ru) | Катионные нейротоксины | |
NZ621196A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
EP3212663B1 (en) | C1 esterase inhibitor fusion proteins and uses thereof | |
NZ597306A (en) | Mesenchymal stem cell differentiation | |
MX2009004147A (es) | Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1. | |
US10619146B2 (en) | Non-cytotoxic protein conjugates | |
CA2725601A1 (en) | Supercharged proteins for cell penetration | |
MXPA01007956A (es) | Polipeptido antimicrobiano/neutralizador de endotoxina. | |
NZ603348A (en) | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof | |
US9012195B2 (en) | Non-cytotoxic protein conjugates | |
HK1089788A1 (en) | A recombinant protein with cancer suppression action, its encoding gene and use | |
NZ614557A (en) | Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use | |
JP2020530283A (ja) | 新規治療学的酵素融合タンパク質及びその用途 | |
MX2022007546A (es) | Interferon-alfa-2 modificado que tiene inmunogenicidad reducida. | |
CN111050784B (zh) | 截短的豚鼠l-天冬酰胺酶变体及其使用方法 | |
MX2022003598A (es) | Composicion farmaceutica, que comprende la proteina galectina 9 recombinante estabilizada, para la prevencion o el tratamiento de la artritis reumatoide y enfermedades oseas. | |
MX2022008748A (es) | Administración oral de péptidos. | |
EP4245311A1 (en) | Use of therapeutic enzyme fusion protein for preventing and treating kidney disease caused or accompanied by fabry's disease | |
WO2003016505A2 (en) | Kgf polypeptide compositions | |
AU2002326742A1 (en) | KGF polypeptide compositions |